Abstract
The efficacy of restoration of cellular immunity in therapy of patients with certain chronic in-infectious or neoplastic diseases is under evaluation in several centers. Theoretically, a substance such as transfer factor is an ideal candidate for this therapy. Transfer factor, a dialyzable substance from blood leukocytes, selectively endows recipients with the cellular immune responses of the leukocyte donors, but does not induce antibody synthesis. Moreover, it does not contain intact leukocytes and therefore does not sensitize the recipient to HL-A antigens and cannot induce graft versus hostdisease. This review summarizes the current status of transfer factor therapy and points out the need for controlled clinical trials.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
